Medical Science News

RSS

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

National Jewish Health scientists identify signaling pathway for ALI

Researchers at National Jewish Health have discovered a signaling pathway that is crucial to the devastating effects of acute lung injury. The data, obtained from cells, animals and ALI patients, suggest several potential therapeutic targets. Experimental blockade of one of the targets significantly reduced flooding of the lungs that is the hallmark of ALI.

31 Jan 2011

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Maxygen, a biotechnology company focused on the development of improved protein drugs, today announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic that is being developed by Perseid Therapeutics LLC, Maxygen's majority-owned subsidiary, in collaboration with Astellas Pharma Inc. for the treatment of rheumatoid arthritis and potentially other autoimmune indications.

31 Jan 2011

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.

31 Jan 2011

Scientists to commence new DNA vaccine trial for use in patients with leukemia

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.

31 Jan 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

Warwick research opens new strategy in vehicle design for drug release

The ability of some forms of plankton and bacteria to build an extra natural layer of nanoparticle-like armour has inspired chemists at the University of Warwick to devise a startlingly simple way to give drug bearing polymer vesicles (microscopic polymer based sacs of liquid) their own armoured protection.

31 Jan 2011

EU grants 3.3 million to AMP for gene therapy development against AIP

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Union has finalized a EUR 3.3 million grant to the AIPGENE consortium, of which AMT is a member, for the development of a gene therapy product for Acute Intermittent Porphyria.

31 Jan 2011

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

Retired San Francisco real estate developer Douglas Rosenberg says he has a new job - helping to find a cure for Alzheimer's disease. Through the Ellen and Douglas Rosenberg Foundation, the venture philanthropist is betting at least $3.5 million that Buck faculty Dale Bredesen, MD has the correct take on how to thwart the memory robbing disease that affects over 5 million Americans.

31 Jan 2011

Omega-3 deficieny may play a role in neuropsychiatric disorders: Study

Researchers from Inserm and INRA and their collaborators in Spain collaboration, have studied mice fed on a diet low in omega-3 fatty acid. They discovered that reduced levels of omega-3 had deleterious consequences on synaptic functions and emotional behaviours.

30 Jan 2011

Scientists convert adult skin cells into cardiomyocytes using direct reprogramming strategy

Scripps Research Institute scientists have converted adult skin cells directly into beating heart cells efficiently without having to first go through the laborious process of generating embryonic-like stem cells. The powerful general technology platform could lead to new treatments for a range of diseases and injuries involving cell loss or damage, such as heart disease, Parkinson's, and Alzheimer's disease.

30 Jan 2011

Research shows nestin regulates formation of neuromuscular junction

In a study published in the Jan. 30, 2011, advance online edition of Nature Neuroscience, Salk Institute of Biological Studies investigators led by Kuo-Fen Lee, PhD., show that nestin has reason for being in a completely different cell type--muscle tissue.

30 Jan 2011

PPTA offers new DVD on plasma donation

Anyone curious about what to expect as a plasma donor and how plasma contributes to lifesaving medicines can now learn about the process thanks to a new DVD from the Plasma Protein Therapeutics Association.

29 Jan 2011

EA receives CLIA certification for clinical laboratory testing

Expression Analysis, a leading provider of genomic services for clinical trials and research, announced today it has received CLIA certification. This milestone comes as the company enters its tenth year of providing genomic expertise; something the company refers to as "Genomic Know-How.

29 Jan 2011

ISU researchers study parasites that cause NTDs in humans

Richard Martin, DVM, PhD, a biomedical sciences professor at Iowa State University's College of Veterinary Medicine, has devoted his 35-year career to studying nematode parasites. These parasites infect approximately one-quarter of the world population, producing debilitating symptoms that devastate the lives and economies of many of the world's underdeveloped and impoverished areas.

29 Jan 2011

Etanercept can restore responsiveness to pain-relieving effects of morphine: Study

A drug called etanercept can restore responsiveness to the pain-relieving effects of morphine in rats that have developed morphine tolerance, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

29 Jan 2011

Genetic study helps investigators solve medical mysteries

The mystery began in 1976. Adolfo Pampena was diagnosed with a rare form of cancer that caused a strange combination of symptoms and was associated with the occurrence of multiple tumours in his stomach and colon. His medical team was stumped and was unable to answer the most important questions for him and his family: the cause of his disease and the risk for future generations.

29 Jan 2011

Scientists use full genome sequencing to identify precise steps in molecular evolution of S. pneumoniae

Despite penicillin and the dozens of antibiotics that followed it, streptococcus bacteria have remained a major threat to health throughout the world. The reason: the superb evolutionary skills of this pathogen to rapidly alter its genetic makeup.

29 Jan 2011

U-M researchers reveal molecular signals that regulate catch-up growth

University of Michigan researchers have uncovered molecular signals that regulate catch-up growth---the growth spurt that occurs when normal conditions are restored after a fetus, young animal or child has been ill, under stress or deprived of enough food or oxygen to grow properly.

29 Jan 2011

FDA approves Arteriocyte's Magellan MAR01 technology for Phase I trial to treat CLI

Arteriocyte, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Critical Limb Ischemia.

29 Jan 2011

Medical Science News

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

National Jewish Health scientists identify signaling pathway for ALI

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

Scientists to commence new DNA vaccine trial for use in patients with leukemia

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Warwick research opens new strategy in vehicle design for drug release

EU grants 3.3 million to AMP for gene therapy development against AIP

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

Omega-3 deficieny may play a role in neuropsychiatric disorders: Study

Scientists convert adult skin cells into cardiomyocytes using direct reprogramming strategy

Research shows nestin regulates formation of neuromuscular junction

PPTA offers new DVD on plasma donation

EA receives CLIA certification for clinical laboratory testing

ISU researchers study parasites that cause NTDs in humans

Etanercept can restore responsiveness to pain-relieving effects of morphine: Study

Genetic study helps investigators solve medical mysteries

Scientists use full genome sequencing to identify precise steps in molecular evolution of S. pneumoniae

U-M researchers reveal molecular signals that regulate catch-up growth

FDA approves Arteriocyte's Magellan MAR01 technology for Phase I trial to treat CLI

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News